# OnCo record nct07049926 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07049926/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07049926", "NCT07049926" ;
  schema:name "Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy ("@en ;
  schema:alternateName "KEYMAKER-U03"@en ;
  schema:description "A phase 1/2 trial of Belzutifan, Zanzalintinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07049926/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07049926> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2025-07-20" ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:drugs <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/drugs/zanzalintinib/> ;
  onco:companies <https://onco.cc/companies/merck/> .